Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

Century Therapeutics (IPSC) presented preclinical data for CNTY-813, a type 1 diabetes therapy, at a diabetes conference. The data showed glycemic control in mice for over 11 months. The company plans to submit an IND application in Q4 2026 and expects initial clinical data in 2H 2027, pending FDA alignment and study completion.

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa